Citadel Advisors
KRBP

Citadel Advisors’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Citadel Advisors’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-403
Closed -$2.18K – 16059
2022
Q4 		$2.18K Buy
+403
New +$3.24K ﹤0.01% 14371
2022
Q2 		– Sell
-3,810
Closed -$98K – 14647
2022
Q1 		$98K Sell
3,810
-5,990
-61% -$177K ﹤0.01% 12305
2021
Q4 		$450K Sell
9,800
-1,400
-13% -$95.4K ﹤0.01% 9958
2021
Q3 		$1.03M Buy
+11,200
New +$1.16M ﹤0.01% 8080

Other funds holding KRBP

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's KRBP Position: Q4 2022 in Review

Citadel Advisors sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q4 2022, closing a stake of 1,329 shares — an estimated $10.7K sold.

Citadel Advisors first reported a position in KRBP in Q4 2020 and held it in 7 quarters. The position peaked at $203K in Q1 2021. 12 funds tracked by Wall St. Rank hold KRBP as of Q4 2022.

  • Citadel Advisors reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 1,329 Kiromic BioPharma, Inc. Common Stock shares in Q4 2022, an estimated $10.7K.
  • Citadel Advisors first reported a position in Kiromic BioPharma, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • Citadel Advisors's Kiromic BioPharma, Inc. Common Stock position peaked at $203K in Q1 2021.
  • 12 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.